SCHEMBL4399162

SCHEMBL4399162

CCOc1cc(O)c(F)c(N2Cc3cnc(NC4CCC(N(C)C)CC4)nc3N(C3CC3)C2=O)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.44
CSF1R P07333 13/20 0.44
FGFR4 P22455 5/20 0.42
FGFR1 P11362 4/20 0.42
FGFR2 P21802 4/20 0.42
FGFR3 P22607 4/20 0.42
FYN P06241 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
PRKACA P17612 1/20 0.39
PRKACG P22612 1/20 0.39
PRKACB P22694 1/20 0.39
MAPK1 P28482 1/20 0.39
KDR P35968 1/20 0.39
EPHB3 P54753 1/20 0.39
TNK2 Q07912 1/20 0.38
MAP4K2 Q12851 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406760 0.97 FGFR4 (0.44) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4398427 0.92 EGFR (0.47) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4402988 0.92 EGFR (0.45) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4395912 0.91 FGFR4 (0.40) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL5379285 0.90 FGFR4 (0.47) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4403342 0.90 FGFR4 (0.40) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4405576 0.90 FGFR4 (0.46) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4411825 0.89 FGFR4 (0.42) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4397737 0.88 FGFR4 (0.42) EGFRCSF1RFGFR4FGFR1FGFR2
SCHEMBL4410438 0.88 FGFR4 (0.48) EGFRCSF1RFGFR4FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 EGFR 141/4885CSF1R 900/4885FGFR4 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.